Doximity Stock Spiked More Than 70% in After-Hours Trading on Q1 Earnings. Here’s Why.
Doximity (DOCS) reported fiscal Q1 2027 revenue of $156.62M, up 7% YoY, and adjusted EBITDA of $74.77M (48% margin). Management raised full-year revenue guidance to $671M-$681M and said new AI search contracts, not legacy pharma, drove the increase. Doximity Ask showed a 4.8% error rate in the NOHARM study. The stock spiked over 70% after hours.
How this was made
The 30-second read
Why it matters
The article frames the earnings as a “reset” because management raised full-year revenue guidance and points to AI search contracts and usage metrics, with most AI search revenue expected in Q3.
Market read
Traders can reassess DOCS based on the combination of Q1 beat, raised full-year guidance, and a defined AI search ramp timeline into Q3.
What to watch
Gross margin fell to 88% from 91% due to higher AI compute spend, and Q2 revenue guidance implies only ~1% growth versus an elevated prior-year comparison.
Background
Doximity’s stock had fallen sharply over the prior year, and the company is investing in an AI search product launched in late April.
Ticker impact
Doximity reported Q1 revenue of $156.62M, cleared the high end of guidance, and raised full-year revenue guidance by $6M to $671M-$681M.
Bullish near-term bias with follow-through risk if Q2 revenue guidance or the Q3 AI search ramp underdelivers.
The article provides specific Q1 results, margin/EBITDA beats, and explicit full-year guidance increase, plus a stated AI search ramp timing (most revenue in Q3) that can extend volatility into the next earnings cycle.
Market effects
Highlights monetization and validation pathways for clinical AI tools, potentially improving sentiment for health-tech AI-adjacent software.
No specific regional spillover beyond US-listed health-tech software sentiment.
Limited; story is company-specific with US health system client validation.
Counterpoint
The quarter booked no AI search revenue yet, so the guidance raise may be front-loaded by contract conversations rather than realized earnings power.
Key entities
- companyDoximity
DOCS, reported Q1 results, raised full-year guidance, and tied the outlook to newly signed AI search contracts and usage growth.
- clinical studyNOHARM study
Independent trial comparing 24 clinical AI models on 1,100 patient cases; Doximity Ask posted the lowest error rate (4.8%).
- health system clientsNorthwestern and Penn Medicine
Named as recent AI search wins contributing to the stated signed health system client count (165).
